Respiratory failure & ventilation
Minimally invasive extracorporeal CO2 removal in hypercapnic respiratory failure: a prospective observational study
Authors' conclusion
miECCO2R delivered via an RRT platform appears to be a safe and effective method of controlling hypercapnia and facilitating lung-protective ventilation in patients with ARDS.
Study context
- Population
- ICU patients with mild-to-moderate acute respiratory distress syndrome (ARDS) and persistent hypercapnia despite escalated ventilation
- Participants
- 20 patients
- Exposure
- Standalone minimally invasive ECCO2R (miECCO2R) vs miECCO2R combined with continuous renal replacement therapy (RRT)
- Standalone miECCO2Rn = 11
- miECCO2R + continuous RRTn = 9
- Outcome
- Efficacy of miECCO2R
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
PaCO2 (all patients) · within 24 h
Median CO2 clearance rate, mL/min
64.5
Observational data: associations, not effects.
Secondary outcomes
Driving pressure · day 5
- Decreased significantly from 22 cm H2O to 15 cm H2O by day 5
- Oxygenation remained stable
Speed of CO2 reduction by treatment group
- Faster CO2 reduction with standalone miECCO2R, probably due to higher blood flow rates
Safety
- No severe adverse events related to the device or therapy
- Circuit clotting managed by system exchange, without clinical consequences
- Moderate decline in platelet counts; no major bleeding complications
Original publication
Minimally invasive extracorporeal CO2 removal in hypercapnic respiratory failure: a prospective observational study. Crit Care. Published 30 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →